Media

Here in the media center you will find a range of resources including our latest and archived press releases, speeches and presentations, information on our social media policy, and our photo and video library.

Press releases

Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof

GSK today announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of psoriasis and atopic dermatitis and back-up programmes for a total consideration of £250 million, including an initial payment of £150 million and a potential future milestone payment of £100 million.